GlassScriptPhysician profile
Shauna Ryder Diggs
NPI 1518027929
$225,331.17
in general payments reported to CMS, 2019-2025
25 companies · $27K in 2025
The $27K reported for 2025 was more than what 95% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $334 · 2020: $1,634 · 2021: $27K · 2022: $76K · 2023: $38K · 2024: $56K · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $121K · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $120,611.02 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lumenis Be INC | $217,108.64 | 2021-2025 | M22, Optilight |
| Lumenis, INC | $4,692.99 | 2020-2021 | |
| Dermavant Sciences, INC. | $753.40 | 2022-2024 | Vtama |
| Pfizer INC. | $366.92 | 2019-2025 | |
| Revance Therapeutics, INC. | $354.39 | 2024 | Daxxify |
| Novartis Pharmaceuticals Corporation | $298.59 | 2019-2025 | |
| Abbvie INC. | $274.28 | 2021-2025 | Botox |
| Organon LLC | $254.24 | 2025 | Vtama |
| Regeneron Healthcare Solutions, INC. | $172.60 | 2021-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $161.49 | 2019-2025 | Tremfya |
| Arcutis Biotherapeutics, INC. | $140.59 | 2024-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $114.42 | 2021-2025 | |
| Leo Pharma INC. | $101.33 | 2022-2025 | Adbry |
| Allergan, INC. | $97.12 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $95.22 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $88.33 | 2019-2025 | Nemluvio |
| Lilly USA, LLC | $64.23 | 2023-2024 | Olumiant, Taltz |
| Merz North America, INC. | $50.96 | 2019-2021 | |
| Incyte Corporation | $37.73 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $23.69 | 2024 | Sotyktu |
| Botanix Sb INC | $23.59 | 2025 | Sofdra |
| Dermira, INC. | $16.88 | 2019 | |
| Journey Medical Corporation | $15.29 | 2022 | |
| Icad, INC | $12.21 | 2022 | |
| Genzyme Corporation | $12.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shauna Diggs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.